Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Dapagliflozin improves kidney function in early T2DM
Last updated July 18, 2026
Key finding
ACR declined markedly from 108.44 mg/g to 65.79 mg/g (P < 0.001).
Dapagliflozin demonstrated significant improvements in key health markers in participants with Type 2 Diabetes Mellitus.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Dapagliflozin demonstrated significant improvements in key health markers in participants with Type 2 Diabetes Mellitus.
Clinical relevance
These findings are clinically significant as they suggest that early intervention with dapagliflozin can lead to rapid improvements in multiple health parameters for patients with Type 2 Diabetes Mellitus, potentially reducing the risk of complications associated with the disease.
Keep in mind
Non-randomized study design limits causal inference. Sample size and demographic details not specified. Long-term effects of dapagliflozin not assessed.
Published in
Journal Reference
Publication details and source links for this paper.
Shahd E, Seya A, Seham N, Sara R, Mohammad Q, Beesan M. Dapagliflozin demonstrates a rapid and multi-organ protective effect when introduced early in T2DM. Diabetology & Metabolic Syndrome. 2026;18:59. doi:10.1186/s13098-026-02094-3
Main Effects
Albumin-to-creatinine ratio decreased by 42.65 mg/g (P < 0.001).
HbA1c dropped by 1.73% (P < 0.001).
Systolic blood pressure reduced by 9.12 mmHg (P < 0.001).
Body mass index decreased by 1.17 kg/m² (P < 0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Dapagliflozin and BMI, Estimated glomerular filtration rate, HbA1c, and 2 more.
This study contributes evidence to
Primary intervention
Dapagliflozin
Primary outcomes
- BMI
- Estimated glomerular filtration rate
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
4
Related topics
5
Evidence pairs
596
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
SGLT2 Inhibitors and HbA1c
Related evidence
Evidence relationship
SGLT2 Inhibitors and Kidney Function
Save evidence
Evidence relationship
SGLT2 Inhibitors and Body Mass Index
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Estimated glomerular filtration rate
Dapagliflozin → Estimated glomerular filtration rate
Dapagliflozin → Estimated glomerular filtration rate
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 85
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 6 studies
Add to Evidence TrackerSystolic blood pressure
Dapagliflozin → Systolic blood pressure
Dapagliflozin → Systolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerUrinary albumin-to-creatinine ratio
Dapagliflozin → Urinary albumin-to-creatinine ratio
Dapagliflozin → Urinary albumin-to-creatinine ratio
Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- ACR improved significantly, indicating reduced kidney stress.
- HbA1c levels decreased, showing better blood sugar control.
- Systolic blood pressure lowered, which may reduce cardiovascular risk.
Who this applies to
- Adults diagnosed with Type 2 Diabetes Mellitus.
- Individuals seeking early intervention for diabetes management.
Keep in Mind
- Results may not be generalizable to all populations.
- Further research is needed to confirm long-term benefits.
- The study did not include a control group for comparison.
Between the Lines
- Non-randomized study design limits causal inference.
- Sample size and demographic details not specified.
- Long-term effects of dapagliflozin not assessed.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and HbA1c, SGLT2 Inhibitors and Body Mass Index.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 79
- Strong
- ImpactScore™
- 85
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 6 studies
View evidenceMedications
SGLT2 Inhibitors → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
View evidenceMedications
SGLT2 Inhibitors → Blood Pressure
Medications
Evidence Intelligence™
- EvidenceScore™
- 73
- Moderate
- ImpactScore™
- 88
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 3 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
6 studies
outcome_hubMeasures HbA1c as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
6 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
3 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
3 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Dapagliflozin and HbA1c
Intervention: DapagliflozinOutcome: HbA1c
6 results
All studies on Dapagliflozin and BMI
Intervention: DapagliflozinOutcome: BMI
3 results
All studies on Dapagliflozin
Intervention: Dapagliflozin
6 results
All studies measuring HbA1c
Outcome: HbA1c
6 results
All studies measuring BMI
Outcome: BMI
3 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does SGLT2 Inhibitors improve HbA1c?
Strong Evidence
SGLT2 Inhibitors may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 78.9 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve kidney function?
Strong Evidence
SGLT2 Inhibitors may improve Kidney Function.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Urinary albumin-to-creatinine ratio
EvidenceScore™ Moderate | EvidenceScore™ 73.1 | strong positive | ConsistencyScore™ Consistent | 1 study
- 2
Estimated glomerular filtration rate
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors affect body mass index?
Strong Evidence
SGLT2 Inhibitors appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Moderate | EvidenceScore™ 73.1 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does SGLT2 Inhibitors improve blood pressure?
Strong Evidence
SGLT2 Inhibitors may improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Systolic blood pressure
EvidenceScore™ Moderate | EvidenceScore™ 73.1 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Dapagliflozin improves metabolic outcomes in type 2 diabetes patientsDapagliflozin may improve RAAS markers in diabetes patientsDapagliflozin shows no long-term harm to bone health in women with diabetesDapagliflozin-linagliptin combo improves glycemic control and organ protectionDapagliflozin improves brain function in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.